- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on PD-1 Antibody
Total 6006 results
-
Ningbo Cancer HospitalUnknownAdvanced Malignancies | PD-1 Antibody | CAR-T CellsChina
-
Shanghai International Medical CenterUnknownAdvanced Solid Tumor | PD-1 Antibody | CAR-T CellsChina
-
Beijing Friendship HospitalNot yet recruiting
-
Sichuan Cancer Hospital and Research InstituteNot yet recruitingIntrahepatic Cholangiocarcinoma | Apatinib | PD-1 Antibody | Transarterial ChemoembolizationChina
-
China Medical University, ChinaNot yet recruitingPD-1 Antibody | Gastrointestinal Tumours | DC-Cell | NK-Cell
-
Shanghai Zhongshan HospitalActive, not recruitingBiliary Tract Cancer | PD-1 Antibody | Lenvatinib | GemoxChina
-
Chinese PLA General HospitalRecruitingHodgkin Lymphoma | Anti-PD-1 Antibody ResistantChina
-
National Cancer Institute (NCI)CompletedHPV16 Anitbody Levels Post Vaccination | HPV18 Antibody Levels Post VaccinationUganda
-
Guohui LiRecruitingPD-1 | Immune Related Adverse EventsChina
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Peking Union Medical College HospitalRecruitingAnlotinib | Anti-PD-1 Antibody | Advanced Pancreatic CancerChina
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaboratorsRecruitingRectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr DeficiencyChina
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Xuanwu Hospital, BeijingUnknownNon-small Cell Lung Cancer | PD-1 Antibody | Lung Cancer Stage II
-
Peking UniversityNot yet recruitingGastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingChemotherapy Effect | Lung Cancer Stage IV | PD-1 Antibody | Lung Cancer Squamous CellChina
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Immunotherapy | Anti-PD-1 Antibody | Persistent Advanced Cervical CarcinomaChina
-
Zhejiang Cancer HospitalNot yet recruitingGastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and SurgeryChina
-
Agenus Inc.CompletedAdvanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1United States
-
Sun Yat-sen UniversityRecruitingPD-1 Inhibitor | G-CSFChina
-
West China HospitalRecruitingBRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal AntibodyChina
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
-
Lei LiRecruitingChemotherapy | Recurrent Cervical Carcinoma | Immune Checkpoint Inhibitors | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma | Albumin-bound PaclitaxelChina
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Chest HospitalUnknownChemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody
-
Sun Yat-sen UniversityCompletedBrain Metastases | NSCLC Stage IV | PD-1 AntibodyChina
-
Shandong New Time Pharmaceutical Co., LTDNot yet recruiting
-
RenJi HospitalRecruitingUpper Urinary Tract Urothelial Carcinoma | Kidney Preservation | HER-2 ADC | PD-1antibodyChina
-
RenJi HospitalRecruitingRadiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug ConjugatesChina
-
Shanghai Jiao Tong University Affiliated Sixth...RecruitingCervical Cancer | Radiotherapy | Neoadjuvant Chemotherapy | PD-1 AntibodyChina
-
Icahn School of Medicine at Mount SinaiRecruitingCancer | Thyroid | PD-1United States
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Xijing HospitalRecruitingPD-1 | Locally Advanced Gastric AdenocarcinomaChina
-
Wuhan Union Hospital, ChinaRecruitingGastroesophageal Junction Cancer | PD-1 | Neoadjuvant ChemoradiotherapyChina
-
Beijing Friendship HospitalNot yet recruitingLymphoma | Hemophagocytic Lymphohistiocytosis | PD-1 Antibody | Epstein-Barr VirusChina
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; National Cancer Institute (NCI)RecruitingRefractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy | MSI-H TumorsUnited States
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
Sun Yat-sen UniversityRecruitingPD-1 Inhibitor | Granulocyte Colony-Stimulating FactorChina
-
The Second Affiliated Hospital of Chongqing Medical...Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...Not yet recruitingChronic Hepatitis b | Anti-PD-1 Antibody | Peg-IFNαChina
-
The Second Affiliated Hospital of Chongqing Medical...Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...Not yet recruitingChronic Hepatitis b | Anti-PD-1 AntibodyChina
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingHIV Infections | HIV-1-infection | PD-L1 Gene MutationChina
-
Beijing Friendship HospitalNot yet recruiting
-
Samsung Medical CenterUnknown
-
University Hospital, LilleTakeda; Laboratoire français de Fractionnement et de Biotechnologies; VitalAire; French Healthcare network for rare immune and hematological disorders (MARIH)Not yet recruitingSpecific Antibody Deficiency | Predominantly Antibody Deficiencies
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
The Second Affiliated Hospital of Harbin Medical...UnknownContract Management PD
-
Peking UniversityUnknownPatients With Digestive System Tumors Resistant to PD-1 Inhibitors
-
Beijing Friendship HospitalCompletedCamrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.Biliary Tract Cancer | Capecitabine | Targeted Molecular Therapy | Anti-PD-1 TherapyChina
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenUnknown